Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telomir Pharmaceuticals

4.58
-0.4500-8.95%
Post-market: 4.590.0100+0.22%17:47 EDT
Volume:307.96K
Turnover:1.49M
Market Cap:136.31M
PE:-8.18
High:5.23
Open:5.10
Low:4.50
Close:5.03
Loading ...

Company Profile

Company Name:
Telomir Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
- -
Office Location:
100 SE 2nd Street,Suite 2000 #1009,Miami,Florida,United States
Zip Code:
33131
Fax:
- -
Introduction:
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Directors

Name
Position
Christopher Chapman, Jr.
Chief Executive Officer and Chairman
Christos Nicholoudis
General Counsel and Director
Brad Kroenig
Director
Craig Eagle
Director
Hugh McColl III
Director
Michael Jerman
Director
Talhia Tuck
Director

Shareholders

Name
Position
Christopher Chapman, Jr.
Chief Executive Officer and Chairman
Nathen Fuentes
Chief Financial Officer, Treasurer and Secretary
Christos Nicholoudis
General Counsel and Director
Michael Roizen
Key Advisor